The Effect of Salutogenic-based Interviewing on Subjective Recovery and Quality of Life in Schizophrenia

NCT ID: NCT06820580

Last Updated: 2025-02-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-02-20

Study Completion Date

2025-12-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Schizophrenia is an inherited, complex, multidimensional syndrome with varying degrees of psychotic, negative, cognitive, mood and motor symptoms. Schizophrenia is a serious public health problem that causes significant losses in the lives of individuals due to both its occurrence at a young age and its prevalence. Ranked by the World Health Organization as one of the top ten diseases contributing to the global burden of disease, it is among the most disabling and economically disastrous medical disorders. The boundaries of schizophrenia remain unclear, indicating a lack of categorical cohesion and the need to reconceptualize it as a broader, multidimensional and/or spectrum construct.

With the discovery of antipsychotic drugs, the symptoms of the disease were alleviated, the level of severity decreased and the length of hospitalization was shortened. However, this led to repeated hospitalizations of patients with chronic course and a revolving door effect occurred. Drug treatment has a limited effect on readjustment to society, improving social relations and increasing self-care activities in individuals with chronic mental illness. Therefore, it is important to support drug treatment with social support programs and various psychosocial approaches. In the past, pathogenic approaches focusing on problems and risk factors have been adopted to promote and maintain health. The salutogenic model developed by medical sociologist Aaron Antonovsky (1987) focuses on the causes of health rather than the factors that cause disease. This model is concerned with the relationship between how people approach stressful situations (such as mental and chronic health conditions and their consequences) and their individual ability to self-manage and cope with these situations. The model is a medical approach that focuses on the causes of health rather than the factors that cause disease.

This study was planned to evaluate the effect of salutogenic approach-based interviewing on subjective recovery and quality of life in individuals diagnosed with schizophrenia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Salutogenesis theory focuses on what contributes to the development of good health and contrasts with pathogenesis explaining disease. The most important question for the salutogenic orientation is how a person identifies and utilizes different resources and thus how health promotion can be supported. It focuses on the creation and maintenance of good health rather than looking for the cause of specific diseases. This is in contrast to the traditional pathogenic model, which focuses on risk factors that play a role in disease occurrence.

The similarity between the core principle of the salutogenic model and the professional purpose of psychiatric nursing is striking. Psychiatric nursing supports the protection and promotion of community mental health, the rehabilitation of disorders and the regaining of the ability to cope with the experiences of suffering and to find meaning in life. Therefore, the model is suitable for many practice areas of psychiatric nurses.

The increasing number of people living with mental health problems in society for many years focuses on the need for recovery from a coping and mental health promotion perspective. The value of salutogenic theory is that it emphasizes coping and health promotion. Although there are numerous empirical applications of salutogenic theory in the field of public health, reviews of salutogenic-based interventions and their impact on population health are limited. Through the salutogenic method, examining deep challenges can provide opportunities to understand how individuals cope during crises and suggest methods to improve the health of the general population. As nursing education and intervention, it is important in terms of emphasizing the need for health promotion and ultimately promoting normal physical and psychological health.

The motto of the Mental Health Action Plan for 2021-2023 is stated as "Implementing an integrated community-based mental health service model in mental health services, monitoring, protecting and improving the mental health of individuals". Subjective recovery is a personally perceived improvement that includes other factors beyond clinical recovery. These factors focus on areas of personal development such as empowerment, having a sense of hope, having confidence in the future, redefining oneself, overcoming stigmatization, establishing supportive relationships, taking responsibility, giving meaning to life and leading a fulfilling life. Subjective well-being and quality of life are increasingly recognized as important treatment outcomes in patients with schizophrenia. Schizophrenia, which usually lasts a lifetime, is a disorder that causes significant problems in quality of life and functioning. Factors such as physical health, adaptability, well-being, economic status and social interaction are among the components of quality of life.

Therefore, this study was planned to evaluate the effect of salutogenic approach-based interviewing on subjective recovery and quality of life in individuals diagnosed with schizophrenia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A randomized controlled study design will be used. It is planned to include 30 individuals in the experimental group and 30 individuals in the control group by randomization method (using the software at http://www.randomizer.org). Participants will be divided into two groups:

Experimental group Control group Individuals in the experimental group will be subjected to a four-week training program and assessments will be made twice, before and after the training. In the control group, no training will be given and the assessments will be conducted twice, four weeks apart.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Salutogenic Approach Based Interview Group

Participants will be offered an 8-session Salutogenic Approach Based Interview Program two days a week.

Group Type EXPERIMENTAL

Salutogenic Approach Based Interview

Intervention Type OTHER

Salutogenic Approach Based Interviewing Program consists of 8 sessions. The interview will be conducted for four weeks and on two specific days of the week. Interviews will be conducted in groups of 6-8 people. The interview will last 30-40 minutes on average.

Control group

There will be no intervention interview. They will continue their normal routines and treatments at the community mental health center.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Salutogenic Approach Based Interview

Salutogenic Approach Based Interviewing Program consists of 8 sessions. The interview will be conducted for four weeks and on two specific days of the week. Interviews will be conducted in groups of 6-8 people. The interview will last 30-40 minutes on average.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years and older
* The participant is in the recovery (remission) period
* Being diagnosed with schizophrenia
* Being suitable for group work

Exclusion Criteria

* The participant experienced an exacerbation (relapse) period
* Presence of hearing and comprehension problems
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ataturk University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Şeyda Erçel

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Şeyda Erçel, MSc

Role: PRINCIPAL_INVESTIGATOR

Ataturk University

Sibel Asi Karakaş

Role: PRINCIPAL_INVESTIGATOR

Ataturk University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Elazığ Community Mental Health Center

Elâzığ, Province, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Şeyda Erçel, MSc

Role: CONTACT

+90 539 493 37 90

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Şeyda Erçel, MSc

Role: primary

+90 539 493 37 90

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AU-SBF-ŞE-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Hippotherapy in Patients With Schizophrenia
NCT06303596 NOT_YET_RECRUITING NA